Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH...( - Uniquely Selective Agent Offer...),Health

- Uniquely Selective Agent Offers Significant Improvement -

CHICAGO, April 28 /PRNewswire-FirstCall/ -- Data to be presented at the American Urological Association's (AUA) Annual Conference show that RAPAFLO(TM) (silodosin) produces rapid and sustained improvements of both irritative and obstructive urinary symptoms associated with BPH, with statistically significant symptom relief within three to four days of starting treatment. RAPAFLO(TM) is a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, launched earlier this month by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals.

A separate abstract, also presented at the conference, found that men taking RAPAFLO(TM) who experienced a treatment related effect called retrograde ejaculation (orgasm with reduced semen) trended to greater improvement in symptom relief and peak flow. This observation suggests that RAPAFLO(TM) relaxes smooth muscles of the lower urinary tract significantly enough to relieve symptoms as well as to induce this effect in some patients. Retrograde ejaculation does not pose a safety concern and is reversible upon discontinuation of treatment. In RAPAFLO(TM) clinical trials, rates of discontinuation due to retrograde ejaculation were low.

"Our observation suggests that retrograde ejaculation is actually an indirect indicator of the relaxation of the smooth musculature that RAPAFLO(TM) induces," said Dr. Steve A. Kaplan, M.D., tenured professor of urology at Weil Cornell Medical College, Cornell University, and an author of one of the AUA abstracts. "For the older BPH patient who experiences retrograde ejaculation, it may be a small tradeoff for the rapid and significant relief of urinary symptoms that treatment with RAPAFLO(TM) offers."

BPH is the number one
'/>"/>